|
ES2560871T3
(es)
|
2007-07-10 |
2016-02-23 |
Apogenix Gmbh |
Proteínas de fusión de colectina de la superfamilia de TNF
|
|
WO2010003766A2
(en)
*
|
2008-06-17 |
2010-01-14 |
Apogenix Gmbh |
Multimeric tnf receptors
|
|
EP2318441A2
(en)
*
|
2008-07-14 |
2011-05-11 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Use of cd95 inhibitors for the treatment of inflammatory disorders
|
|
JP5674155B2
(ja)
|
2008-07-21 |
2015-02-25 |
アポゲニクス ゲゼルシャフト ミット ベシュレンクテル ハフツングApogenix GmbH |
Tnfsf一本鎖分子
|
|
EP2829550B1
(en)
|
2009-01-09 |
2016-11-16 |
Apogenix AG |
Fusion proteins forming trimers
|
|
TWI476001B
(zh)
|
2011-12-26 |
2015-03-11 |
Ind Tech Res Inst |
三倍體Fc融合蛋白及其用途
|
|
JP6373836B2
(ja)
|
2012-07-26 |
2018-08-15 |
ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド |
多量体融合タンパク質ワクチン及び免疫療法
|
|
WO2014100913A1
(en)
*
|
2012-12-24 |
2014-07-03 |
Beijing Anxinhuaide Biotech. Co., Ltd |
Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
|
|
NO2776305T3
(cg-RX-API-DMAC7.html)
|
2014-04-23 |
2018-01-27 |
|
|
|
BR102014031185A8
(pt)
*
|
2014-12-12 |
2021-05-04 |
Fund De Amparo A Pesquisa Do Estado De Sao Paulo Fapesp |
proteína recombinante indutora da apoptose; processo de obtenção da dita proteína e o seu uso no tratamento do câncer
|
|
IL308212A
(en)
|
2015-01-20 |
2024-01-01 |
Igm Biosciences Inc |
Tumor necrosis factor-α receptor binding molecules and their uses
|
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
|
EP3076179A1
(en)
|
2015-03-30 |
2016-10-05 |
Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts |
Diagnosis and treatment of low grade gliomas
|
|
CA2999116A1
(en)
|
2015-09-23 |
2017-03-30 |
Apogenix Ag |
Anti-cd95l antibody
|
|
US20180312545A1
(en)
*
|
2015-11-09 |
2018-11-01 |
Curevac Ag |
Optimized nucleic acid molecules
|
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
|
EP3565888A1
(en)
|
2017-01-06 |
2019-11-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
|
|
US11357841B2
(en)
|
2017-01-06 |
2022-06-14 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
|
|
WO2018209115A1
(en)
|
2017-05-10 |
2018-11-15 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
EP3635097A1
(en)
|
2017-06-05 |
2020-04-15 |
Iovance Biotherapeutics, Inc. |
Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
|
|
WO2019032952A1
(en)
|
2017-08-11 |
2019-02-14 |
The Board Of Trustees Of The University Of Illinois |
TRUNCATED VARIANTS OF INDIA PIG ASPARAGINASE AND METHODS OF USE
|
|
MX2020004967A
(es)
|
2017-11-17 |
2020-08-27 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
|
|
JP2021503885A
(ja)
|
2017-11-22 |
2021-02-15 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
末梢血からの末梢血リンパ球(pbl)の拡大培養
|
|
JP7565795B2
(ja)
|
2017-12-15 |
2024-10-11 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の有益な投与を決定するシステム及び方法並びにその使用方法、並びに腫瘍浸潤リンパ球の有益な投与及びその使用方法
|
|
JP2021509586A
(ja)
|
2018-01-08 |
2021-04-01 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍抗原特異的t細胞について濃縮されたtil製品を生成するためのプロセス
|
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
|
MA51875A
(fr)
|
2018-02-13 |
2020-12-23 |
Iovance Biotherapeutics Inc |
Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
|
|
EP4386080A3
(en)
|
2018-03-29 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2019210131A1
(en)
|
2018-04-27 |
2019-10-31 |
Iovance Biotherapeutics, Inc. |
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
US12473532B2
(en)
|
2018-05-10 |
2025-11-18 |
Iovance Biotherapeutics, Inc. |
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
WO2020018715A1
(en)
|
2018-07-17 |
2020-01-23 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
|
TW202031273A
(zh)
|
2018-08-31 |
2020-09-01 |
美商艾歐凡斯生物治療公司 |
抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療
|
|
SG11202101787XA
(en)
|
2018-09-20 |
2021-04-29 |
Iovance Biotherapeutics Inc |
Expansion of tils from cryopreserved tumor samples
|
|
MX2021004775A
(es)
|
2018-11-05 |
2021-06-08 |
Iovance Biotherapeutics Inc |
Expansion de linfocitos infiltrantes de tumores (tils) usando inhibidores de la via de proteina cinasa b (akt).
|
|
AU2019375416A1
(en)
|
2018-11-05 |
2021-05-27 |
Iovance Biotherapeutics, Inc. |
Selection of improved tumor reactive T-cells
|
|
ES3021682T3
(en)
|
2018-11-05 |
2025-05-27 |
Iovance Biotherapeutics Inc |
Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
|
|
JP2022506586A
(ja)
|
2018-11-05 |
2022-01-17 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の産生のためのプロセスおよび免疫療法におけるその使用
|
|
US20220193131A1
(en)
|
2018-12-19 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
|
|
BR112021016875A2
(pt)
|
2019-03-01 |
2022-01-04 |
Iovance Biotherapeutics Inc |
Processo para expansão de linfócitos de sangue periférico
|
|
MX2021011608A
(es)
|
2019-03-29 |
2021-12-10 |
Myst Therapeutics Llc |
Metodos ex vivo para producir celulas t terapeuticas y composiciones y metodos afines.
|
|
US20220249559A1
(en)
|
2019-05-13 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
|
|
EP4048295A1
(en)
|
2019-10-25 |
2022-08-31 |
Iovance Biotherapeutics, Inc. |
Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
|
|
CN115023270A
(zh)
|
2019-11-27 |
2022-09-06 |
迈斯特治疗公司 |
使用调节剂产生肿瘤反应性t细胞组合物的方法
|
|
JP7749561B2
(ja)
|
2019-12-11 |
2025-10-06 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球(til)の産生のためのプロセス及びそれを使用する方法
|
|
IL295990A
(en)
|
2020-02-27 |
2022-11-01 |
Myst Therapeutics Llc |
Methods for in vitro enrichment and expansion of tumor-reactive t cells and preparations related thereto
|
|
JP2023524108A
(ja)
|
2020-05-04 |
2023-06-08 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
改良された腫瘍反応性t細胞の選択
|
|
JP2023523855A
(ja)
|
2020-05-04 |
2023-06-07 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用
|
|
US20240016918A1
(en)
*
|
2020-08-24 |
2024-01-18 |
Sanofi Pasteur Inc. |
Vaccines against sars-cov-2 infections
|
|
US20230372397A1
(en)
|
2020-10-06 |
2023-11-23 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022076606A1
(en)
|
2020-10-06 |
2022-04-14 |
Iovance Biotherapeutics, Inc. |
Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
|
|
WO2022125941A1
(en)
|
2020-12-11 |
2022-06-16 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors
|
|
US20240299539A1
(en)
|
2020-12-17 |
2024-09-12 |
Iovance Biotherapeutics, Inc. |
Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
|
|
WO2022133149A1
(en)
|
2020-12-17 |
2022-06-23 |
Iovance Biotherapeutics, Inc. |
Treatment of cancers with tumor infiltrating lymphocytes
|
|
WO2022170219A1
(en)
|
2021-02-05 |
2022-08-11 |
Iovance Biotherapeutics, Inc. |
Adjuvant therapy for cancer
|
|
CN117279506A
(zh)
|
2021-03-05 |
2023-12-22 |
艾欧凡斯生物治疗公司 |
肿瘤储存及细胞培养组合物
|
|
JP2024515189A
(ja)
|
2021-04-19 |
2024-04-05 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
細胞免疫療法におけるキメラ共刺激受容体、ケモカイン受容体、及びそれらの使用
|
|
JP2024519029A
(ja)
|
2021-05-17 |
2024-05-08 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
Pd-1遺伝子編集された腫瘍浸潤リンパ球及び免疫療法におけるその使用
|
|
CN117396520A
(zh)
*
|
2021-05-27 |
2024-01-12 |
北京安信怀德生物技术有限公司 |
包含两个trail三聚体的超trail分子
|
|
WO2023009716A1
(en)
|
2021-07-28 |
2023-02-02 |
Iovance Biotherapeutics, Inc. |
Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with kras inhibitors
|
|
EP4404969A1
(en)
|
2021-09-24 |
2024-07-31 |
Iovance Biotherapeutics, Inc. |
Expansion processes and agents for tumor infiltrating lymphocytes
|
|
JP2024541911A
(ja)
|
2021-10-27 |
2024-11-13 |
アイオバンス バイオセラピューティクス,インコーポレイテッド |
患者特異的免疫療法のための細胞の製造を調整するためのシステム及び方法
|
|
CA3237410A1
(en)
|
2021-11-10 |
2023-05-19 |
Friedrich Graf Finck VON FINCKENSTEIN |
Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
|
|
EP4469066A1
(en)
|
2022-01-28 |
2024-12-04 |
Iovance Biotherapeutics, Inc. |
Tumor infiltrating lymphocytes engineered to express payloads
|
|
EP4507704A1
(en)
|
2022-04-15 |
2025-02-19 |
Iovance Biotherapeutics, Inc. |
Til expansion processes using specific cytokine combinations and/or akti treatment
|
|
WO2024030758A1
(en)
|
2022-08-01 |
2024-02-08 |
Iovance Biotherapeutics, Inc. |
Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
|
|
WO2024098024A1
(en)
|
2022-11-04 |
2024-05-10 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes from liquid tumors and therapeutic uses thereof
|
|
WO2024151885A1
(en)
|
2023-01-13 |
2024-07-18 |
Iovance Biotherapeutics, Inc. |
Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
|
|
WO2025101484A1
(en)
|
2023-11-06 |
2025-05-15 |
Iovance Biotherapeutics, Inc. |
Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
|